Institutional investors purchased a net $1.1 million shares of ALXN during the quarter ended March 2013 and now own 98.59% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
| Mutual fund holders | 59.36% |
| Other institutional | 39.23% |
| Individual stakeholders | 1.55% |